EBV LMP-2A Antibody (14B7): sc-101314
- EBV LMP-2A Antibody (14B7) is a rat monoclonal IgG2a, cited in 9 publications, provided at 200 µg/ml
- raised against bacterial TrpE-LMP2A fusion protein
- recommended for detection of LMP-2A of EBV origin by WB, IP and IF
- also available conjugated to Alexa Fluor® 594 (sc-101314 AF594), 200 µg/ml, for IF, IHC(P) and FCM
- See EBV LMP-2A (15F9): sc-101315 for EBV LMP-2A antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for EBV LMP-2A Antibody (14B7). This work is in progress.
QUICK LINKS
SEE ALSO...
EBV LMP-2A Antibody (14B7) is a rat monoclonal IgG2a antibody that detects EBV LMP-2A of Epstein-Barr virus (EBV) by western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). EBV LMP-2A is a 497 amino acid protein that plays a crucial role in the pathogenesis of EBV-associated malignancies, as EBV LMP-2A is expressed on the surface of EBV-infected cells. EBV LMP-2A features a unique structure comprising 12 membrane-spanning domains, a short C-terminal tail, and a long N-terminal segment, which is essential for modulating cellular signaling pathways. The structural configuration of EBV LMP-2A allows interaction with protein tyrosine kinases, leading to the activation of the phosphatidylinositol 3-kinase (PI3K) pathway. This activation prevents apoptosis, thereby providing survival signals to infected cells and promoting tumorigenesis. EBV LMP-2A can mimic B-cell receptor complex signaling in B-cell receptor-negative cells, underscoring EBV LMP-2A′s importance in the survival of mutated cells. Anti-EBV LMP-2A antibody (14B7) is an invaluable tool for researchers studying the mechanisms of EBV-induced malignancies and EBV LMP-2A′s role in cancer biology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
EBV LMP-2A Antibody (14B7) References:
- Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. | Kanegane, H., et al. 2002. Crit Rev Oncol Hematol. 44: 239-49. PMID: 12467964
- Epstein-Barr virus latent membrane protein LMP-2A is sufficient for transactivation of the human endogenous retrovirus HERV-K18 superantigen. | Sutkowski, N., et al. 2004. J Virol. 78: 7852-60. PMID: 15220463
- Pre-B-cell colony formation assay. | Ikeda, M. and Longnecker, R. 2005. Methods Mol Biol. 292: 279-84. PMID: 15507715
- Identification of the WW domain-interaction sites in the unstructured N-terminal domain of EBV LMP 2A. | Seo, MD., et al. 2007. FEBS Lett. 581: 65-70. PMID: 17174309
- EBV LMP-2A employs a novel mechanism to transactivate the HERV-K18 superantigen through its ITAM. | Hsiao, FC., et al. 2009. Virology. 385: 261-6. PMID: 19070345
- Expression of latent membrane proteins in Epstein‑Barr virus-transformed lymphocytes in vitro. | Tang, Y., et al. 2014. Mol Med Rep. 10: 1117-21. PMID: 24919846
- Update on Epstein-Barr virus and gastric cancer (review). | Shinozaki-Ushiku, A., et al. 2015. Int J Oncol. 46: 1421-34. PMID: 25633561
- Expression of LMP and EBNA genes in Epstein-Barr virus-associated lymphomas in Hu-PBL/SCID mice. | Tang, Y., et al. 2016. Oncol Rep. 35: 905-11. PMID: 26548532
- The interplay between Epstein-Bar virus (EBV) with the p53 and its homologs during EBV associated malignancies. | Chatterjee, K., et al. 2019. Heliyon. 5: e02624. PMID: 31840114
- EBV-NK cells interactions and lymphoproliferative disorders. | Kanegane, H., et al. 1998. Leuk Lymphoma. 29: 491-8. PMID: 9643562
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EBV LMP-2A Antibody (14B7) | sc-101314 | 200 µg/ml | $322.00 | |||
EBV LMP-2A Antibody (14B7) Alexa Fluor® 594 | sc-101314 AF594 | 200 µg/ml | $364.00 |